Founded in 2015, Geneoscopy has raised more than $100 million in financing as it's sought to bring its colorectal cancer ...

Geneoscopy appointed Matt Sargent as Chief Commercial Officer and Tyler Aldredge as VP of Operations to support the ...

Life sciences company Geneoscopy received FDA approval for its noninvasive colorectal cancer screening test, ColoSense. 2. Ambu earned FDA clearance for its aScope Gastro Large and Ambu aBox 2. The ...

Meanwhile, a competitor has received federal approval for a stool-based colon cancer screening test to rival Exact Sciences' ...

This time a positive result for a cancer screening test brought good news, as Geneoscopy Inc. secured U.S. FDA approval for ...

Evercore and Cowen analysts expect Colosense to have a limited impact on Exact Sciences’ rival Cologuard test.

The FDA has approved ColoSense, a noninvasive colorectal cancer screening test, for adults 45 years of age and older who are at average risk of developing colorectal cancer.

Despite the approval of Geneoscopy’s Colosense, Souda expects limited impact on Exact Sciences at current levels, noting that the performance of Geneoscopy’s assay is similar to Cologuard’s existing ...

Life sciences company Geneoscopy received FDA approval for its noninvasive colorectal cancer screening test, ColoSense. ColoSense is the first noninvasive colorectal cancer screening test to offer a ...

Relative to fecal immunochemical testing, the multitarget stool RNA test ColoSense showed a significant improvement in ...

A screening test has been approved by the FDA for adults 45 years of age or older with an average risk for developing colorectal cancer.